Brokerages Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) PT at $48.71

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the nineteen brokerages that are covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $48.71.

Several research analysts have issued reports on the company. StockNews.com upgraded Intellia Therapeutics to a "sell" rating in a research note on Friday, November 8th. Canaccord Genuity Group reiterated a "buy" rating and set a $90.00 target price on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. Oppenheimer cut their price target on shares of Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating for the company in a report on Monday, January 13th. Wedbush reaffirmed a "neutral" rating and set a $10.00 price objective (down previously from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. Finally, Chardan Capital lifted their target price on shares of Intellia Therapeutics from $88.00 to $91.00 and gave the company a "buy" rating in a research note on Monday, November 18th.

Insiders Place Their Bets

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the firm's stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the sale, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. This trade represents a 2.77 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Over the last three months, insiders have sold 28,735 shares of company stock worth $349,909. Company insiders own 3.20% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Eastern Bank acquired a new position in Intellia Therapeutics during the 3rd quarter worth approximately $41,000. Values First Advisors Inc. acquired a new position in Intellia Therapeutics during the third quarter worth $54,000. KBC Group NV boosted its holdings in Intellia Therapeutics by 62.4% during the fourth quarter. KBC Group NV now owns 6,093 shares of the company's stock worth $71,000 after purchasing an additional 2,340 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Intellia Therapeutics by 27.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company's stock valued at $77,000 after buying an additional 794 shares during the last quarter. Finally, Blue Trust Inc. lifted its position in Intellia Therapeutics by 182.7% during the 3rd quarter. Blue Trust Inc. now owns 4,189 shares of the company's stock worth $94,000 after buying an additional 2,707 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company's stock.

Intellia Therapeutics Stock Performance

Shares of NASDAQ:NTLA traded up $0.52 during midday trading on Thursday, reaching $10.64. 1,051,764 shares of the company's stock were exchanged, compared to its average volume of 3,135,716. The company's 50 day simple moving average is $12.41 and its two-hundred day simple moving average is $17.78. Intellia Therapeutics has a 12 month low of $9.25 and a 12 month high of $34.87. The firm has a market capitalization of $1.08 billion, a PE ratio of -1.94 and a beta of 1.83.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating analysts' consensus estimates of ($1.37) by $0.03. The company had revenue of $9.10 million for the quarter, compared to analyst estimates of $8.28 million. During the same period in the previous year, the firm posted ($1.38) earnings per share. The firm's revenue for the quarter was down 24.1% compared to the same quarter last year. On average, research analysts anticipate that Intellia Therapeutics will post -5.09 earnings per share for the current year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.